Ecsc,
CR is expected as most of the US based bio companies refer to hold at least 3 years of operational cash reserve. I would think management will try to raise additional $50mil USD at least this year.
Lets just hope that they do some meaningful marketing efforts to intos before having any placement at a little premium for a change..
count down to strategic review, page-4
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)